Purpose: α-fetoprotein (AFP)-producing gastric cancer is a rare tumor with high rates of liver metastasis and a poor prognosis. Many studies have been performed but there have been no comprehensive investigations of the clinicopathological and prognosis. Materials and Methods: Six hundred ninety four patients with gastric cancer who underwent a curative gastric resection in Hanyang University Hospital from February 2001 to December 2008 were evaluated retrospectively after excluding active or chronic hepatits, liver cirrhosis and preoperative distant metastasis. Among them, thirty five patients had an elevated serum level of AFP (>7 ng/ml) preoperatively. The clinicopathological features of AFP-producing gastric cancer were analyzed. Results: There was poorer differentiation, a higher incidence of lymph node metastasis, more marked lymphatic and vascular invasion in the AFP-positive group than in the AFP-negative group. The 5-year survival rate of the AFP-positive group was significantly poorer than that in the AFP-negative group (66% vs. 80%, P=0.002). A significantly higher incidence of liver metastasis was observed in the AFPpositive group than in the AFP-negative group (14.3% vs. 3.6%, P=0.002) with a shorter median time period from the operation to the metachronous liver metastasis (3.7 months vs. 14.1 months, P=0.043). Multivariate survival analysis revealed the depth of invasion, degree of lymph node metastasis and AFP-positivity to be the independent prognostic factors. Conclusions: AFP-producing gastric cancers have an aggressive behavior with a high metastatic potential to the liver. In addition, their clinicopathological features are quite different from the more common AFP-negative gastric cancer.
Introduction
Alpha-fetoprotein (AFP) was initially found in the human fetus and is normally produced in the fetal liver and yolk sac.(1) The elevation of serum AFP level is often considered as abnormal in adults, and in clinical practice, AFP is a well-known tumor marker for screening or monitoring hepatocellular carcinoma and yolk sac tumor. Some studies showed that AFP could be produced in other cancers including primary gastric carcinoma. (2) A case of AFP-producing gastric cancer with liver metastasis was first reported in 1970. Since then, scattered cases of early and advanced AFP-producing gastric cancer have been reported, some of them showing poor prognosis with lymphatic and venous microinvasion along with high rates of liver metastasis, of both synchronous and metachronous types. (3) (4) (5) Furthermore, AFPproducing gastric cancer showed significantly poorer survival than the AFP-negative group. (6) It is reported that AFP-producing gastric cancer often has high proliferative activity, weak apoptosis and rich neovascularization, as compared with AFP-negative gastric cancer. (7) Recently, others have also reported the aggressiveness of AFP-producing gastric cancer after observing frequent c-Met overexpression in AFP-producing gastric cancer, as compared with stage-matched gastric cancer not producing AFP. (8) fied here, especially with respect to the characteristics of liver metastasis.
Materials and Methods
In this study, 694 patients with histologically confirmed primary gastric cancer who underwent curative gastric resection with D2 or more extended lymph node dissection at Hanyang University Hospital from February 2001 to December 2008 were selected and evaluated retrospectively. A total of 25 patients with active or chronic hepatitis and liver cirrhosis, as well as 30 patients with preoperative distant metastasis, were excluded from this study (Fig. 1) (Fig. 2, 3 ).
Clinicopathological features according to AFP positivity
Clinicopathological characteristics were comparatively analyzed by dividing samples into AFP-positive and AFP-negative groups (Table 1) . In histological classification, a poorer differentiation was observed more frequently in the AFP-positive group as compared with the AFP-negative group. There was a higher incidence of Table 2 ). The 5-year survival rate of the AFP-positive group was significantly poorer than that of the AFP-negative group. In gastric cancer with liver metastasis, the AFP-positive group also had a significantly poorer 5-year survival rate compared to the AFP-negative group No. = number; WEL = well differentiated tubular adenocarcinoma; MOD = moderately differentiated tubular adenocarcinoma; POR = poorly diff erentiated tubular adenocar cinoma; AFP = alpha-fetoprotein. *UICC TNM staging system (6 th ed). ( Fig. 4 ).
Liver metastasis
We observed a higher incidence of liver metastasis in the AFPpositive group compared with the AFP-negative group (14.3% vs.
3.6%), along with a higher incidence of multiple liver metastases rather than solitary liver metastasis (60% vs. 16.7%) ( Table 3 ).
The time period from the operation to metachronous liver me- There was no significant correlation between AFP positivity and the location of recurrence except for liver metastasis (which included overlapped metastasis), as shown in Table 4 .
Multivariate survival analysis according to clinicopathological factors
As there is a possibility of mutual correlation between significant variables observed in univariate survival analysis, the TNM stage was excluded initially and when the rest of the significant variables were added to the Cox proportional hazard models. Significant prognostic factors included the following: depth of invasion, lymph node metastasis and AFP, as shown in Table 5 . Multivariate analysis limited to gastric cancer patients with liver metastasis revealed that AFP and lymphatic invasion were independent prognostic fac- tors, as shown in Table 6 . Pre-and postoperative chemotherapy can affect survival analysis. In order to eliminate the bias from survival analysis, pre-and postoperative chemotherapy must be fully considered. Unfortunately, diverse chemotherapy strategies and differing treatment times were applied to each one of our patients. Considering chemotherapy as an analysis factor created a barrier to precise survival analysis. Therefore, chemotherapy was excluded as an analysis factor in our study.
The prevalence of AFP-producing gastric cancer is reported to be 6.2~6.3% (18, 19) in Korea, 1.3~5% in Japan,(20,21) 2.5% in
China (22) How can we explain this aggressive clinical behavior of AFPproducing gastric cancer? Unfortunately, the exact molecular mechanism that could explain this is still unclear and far limited.
Generally, AFP-producing gastric cancer is associated with higher proliferative activity, weaker apoptosis and richer neovascularization. Some authors suggested that high levels of CD10 and low levels of CDX expression might be associated with aggressive behavior, particularly in hepatoid carcinoma. (24) Others, as previously mentioned, proposed that overexpression of c-Met was frequently observed in AFP-positive gastric cancer and that this receptor, Depth of invasion, lymph node metastasis and AFP were found to be the independent prognostic factors in multivariate analysis, with AFP having a hazard ratio of 2.699. This value is a slightly low hazard ratio compared to other significant values, thus implying that AFP might not be a major risk factor in gastric cancer.
However, when multivariate analysis was limited to gastric cancer with liver metastasis, the hazard ratio increased to 4.298, showing that AFP could be an important risk factor when liver metastasis has occurred.
AFP-producing gastric cancer is a small subgroup of gastric cancer with a high likelihood of rapid metastasis to the liver. Its aggressive biological behavior in addition to its unique clinicopathological features should be studied further at the cellular and molecular levels in order to develop an effective multimodal therapy against AFP-producing gastric cancer.
